Partnering in a late-stage trial
According to BioNTech, the two companies will work together on a late-stage study to evaluate the combination. Key points: The change of comparator is significant, because showing benefit over an already approved targeted drug sets a higher bar than beating chemotherapy alone.
- The trial will test BioNTech’s pumitamig with Gilead’s Trodelvy, approved by the US Food and Drug Administration (FDA).
- BioNTech plans to update its study to compare the combination with Trodelvy alone, instead of with chemotherapy.
- BioNTech will sponsor and lead the trial, while Gilead will supply Trodelvy.
- The planned changes to the trial design require approval from health regulators.
Triple-negative breast cancer
Triple-negative breast cancer is an aggressive form of the disease that lacks common treatment targets such as hormone receptors or HER2, so many standard targeted therapies do not work. According to BioNTech, it accounts for about 10% to 15% of breast cancer cases.

















